A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

NCT05247489 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Vitiligo

Interventions

DRUG: Ruxolitinib 1.5% cream
DEVICE: NB-UVB phototherapy

Sponsor

Incyte Corporation